Genotype–phenotype correlation in PRKN-associated Parkinson’s disease
Poornima Jayadev Menon,Sara Sambin,Baptiste Criniere-Boizet,Thomas Courtin,Christelle Tesson,Fanny Casse,Melanie Ferrien,Louise-Laure Mariani,Stephanie Carvalho,Francois-Xavier Lejeune,Sana Rebbah,Gaspard Martet,Marion Houot,Aymeric Lanore,Graziella Mangone,Emmanuel Roze,Marie Vidailhet,Jan Aasly,Ziv Gan Or,Eric Yu,Yves Dauvilliers,Alexander Zimprich,Volker Tomantschger,Walter Pirker,Ignacio Álvarez,Pau Pastor,Alessio Di Fonzo,Kailash P. Bhatia,Francesca Magrinelli,Henry Houlden,Raquel Real,Andrea Quattrone,Patricia Limousin,Prasad Korlipara,Thomas Foltynie,Donald Grosset,Nigel Williams,Derek Narendra,Hsin-Pin Lin,Carna Jovanovic,Marina Svetel,Timothy Lynch,Amy Gallagher,Wim Vandenberghe,Thomas Gasser,Kathrin Brockmann,Huw R. Morris,Max Borsche,Christine Klein,Olga Corti,Alexis Brice,Suzanne Lesage,Jean Christophe Corvol,
DOI: https://doi.org/10.1038/s41531-024-00677-3
2024-03-29
Abstract:Abstract Bi-allelic pathogenic variants in PRKN are the most common cause of autosomal recessive Parkinson’s disease (PD). 647 patients with PRKN -PD were included in this international study. The pathogenic variants present were characterised and investigated for their effect on phenotype. Clinical features and progression of PRKN -PD was also assessed. Among 133 variants in index cases ( n = 582), there were 58 (43.6%) structural variants, 34 (25.6%) missense, 20 (15%) frameshift, 10 splice site (7.5%%), 9 (6.8%) nonsense and 2 (1.5%) indels. The most frequent variant overall was an exon 3 deletion ( n = 145, 12.3%), followed by the p.R275W substitution ( n = 117, 10%). Exon3, RING0 protein domain and the ubiquitin-like protein domain were mutational hotspots with 31%, 35.4% and 31.7% of index cases presenting mutations in these regions respectively. The presence of a frameshift or structural variant was associated with a 3.4 ± 1.6 years or a 4.7 ± 1.6 years earlier age at onset of PRKN -PD respectively ( p < 0.05). Furthermore, variants located in the N-terminus of the protein, a region enriched with frameshift variants, were associated with an earlier age at onset. The phenotype of PRKN -PD was characterised by slow motor progression, preserved cognition, an excellent motor response to levodopa therapy and later development of motor complications compared to early-onset PD. Non-motor symptoms were however common in PRKN -PD. Our findings on the relationship between the type of variant in PRKN and the phenotype of the disease may have implications for both genetic counselling and the design of precision clinical trials.
neurosciences